NoName_3327 → 6-[4-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidin-1-yl]-pyrimidine-4-carboxylic acid(1H-indazol-4-yl)-amide

HRID 74695

반응식

HRID 74695 반응식
[CH3:1][O:2][C:3]1[CH:29]=[CH:28][C:6]2[NH:7][C:8](=[O:27])[N:9]([CH:12]3[CH2:17][CH2:16][N:15]([C:18]4[CH:23]=[C:22]([C:24]([OH:26])=O)C=C[N:19]=4)[CH2:14][CH2:13]3)[CH2:10][CH2:11][C:5]=2[CH:4]=1.[NH2:30][C:31]1[CH:39]=[CH:38][CH:37]=[C:36]2[C:32]=1[CH:33]=[N:34][NH:35]2.[CH3:40][N:41](C(ON1N=NC2C=CC=CC1=2)=[N+](C)C)C.[B-](F)(F)(F)F>CN(C=O)C>[NH:35]1[C:36]2[C:32](=[C:31]([NH:30][C:24]([C:22]3[CH:23]=[C:18]([N:15]4[CH2:16][CH2:17][CH:12]([N:9]5[CH2:10][CH2:11][C:5]6[CH:4]=[C:3]([O:2][CH3:1])[CH:29]=[CH:28][C:6]=6[NH:7][C:8]5=[O:27])[CH2:13][CH2:14]4)[N:19]=[CH:40][N:41]=3)=[O:26])[CH:39]=[CH:38][CH:37]=2)[CH:33]=[N:34]1

참가 물질

5

실험 절차

100 mg (0.25 mmol) 4-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4′-carboxylic acid and 34 mg (0.25 mmol) 4-amino-indazole in 74 mμL (0.53 mmol) TEA and 1.5 mL DMF were combined with 89 mg (0.28 mmol) TBTU and the mixture was stirred overnight at RT. Then the reaction mixture was purified by preparative HPLC-MS. The product-containing fractions were combined and freeze-dried.

후처리

  1. customThen the reaction mixture was purified by preparative HPLC-MS
  2. customfreeze-dried

출처 및 근거

ORD 기록
ord-2832dc2c146b469cb93d3bc6b833b7f1
출처 데이터셋
uspto-grants-2014_09
특허 번호
US08829006B2

연결된 노트

불러오는 중…